GLP-1s can cut the risk of Alzheimer’s. What does that mean for Novo Nordisk?

A new study found that patients taking GLP-1s to treat type 2 diabetes have a lower risk of developing Alzheimer’s disease, potentially opening the door to another lucrative category for Novo Nordisk. Diabetes patients on ...